Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report
Oncol Lett. 2024 Mar 22;27(5):220. doi: 10.3892/ol.2024.14354. eCollection 2024 May.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare and aggressive tumor with an unknown pathogenesis. Myelofibrosis (MF) is a type of myeloproliferative neoplasm. MF can be secondary to several hematological malignancies, including chronic myeloid leukemia, myelodysplastic syndrome and hairy cell leukemia. In the present report, a rare case of BPDCN secondary to MF is described. A 70-year-old male patient developed a large purplish-red rash with recurrent symptoms. BPDCN was confirmed by immunohistochemistry o...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Fuyi Luo Bingjie Li Jing Li Yan Li Source Type: research
LncRNA HOXA ‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis
In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA-AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these ...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Tijun Xiao An Yan Lifang Tan Hongwei Zhu Wenzhe Gao Source Type: research
hsa ‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel
Oncol Lett. 2024 Mar 21;27(5):219. doi: 10.3892/ol.2024.14350. eCollection 2024 May.ABSTRACTLung cancer is the leading cause of cancer-related morbidity and mortality worldwide. The initial treatment of lung cancer depends on the definition of the tumor type and its staging. The most common treatment is chemotherapy, and the first-line treatment is a combination of carboplatin and paclitaxel. Although this treatment has good efficacy, there is a high prevalence of adverse events, particularly hematological reactions. Studies on new biomarkers related to these adverse events, such as circulating microRNAs (miRNAs/miRs), are...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Pedro Eduardo Nascimento Silva Vasconcelos Cec ília Souto Seguin Arist óteles de Souza Barbeiro Lair Zambon Helen Naemi Honma Maur ício Wesley Perroud Murilo Vieira Geraldo Eder de Carvalho Pincinato Patricia Moriel Source Type: research
Skipped sentinel lymph node basin in a patient with forearm cutaneous melanoma: A case report
Oncol Lett. 2024 Mar 26;27(5):233. doi: 10.3892/ol.2024.14366. eCollection 2024 May.ABSTRACTSentinel lymph node biopsy is an important tool in the management of malignant melanoma, particularly in predicting micrometastasis to regional lymph nodes. Cases of secondary drainage to lymph nodes outside of conventional nodal basins and overall unusual lymph node localization have been reported. The present study reports a unique case of a 'skipped sentinel lymph node basin' pattern in a patient with a right forearm malignant melanoma. Lymphatic mapping using cutaneous lymphoscintigraphy revealed localization at the right suprac...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Olivier F Noel James Clune Source Type: research
FOXP2 inhibits the aggressiveness of lung cancer cells by blocking TGF β signaling
Oncol Lett. 2024 Mar 26;27(5):227. doi: 10.3892/ol.2024.14361. eCollection 2024 May.ABSTRACTLung cancer is associated with high morbidity and mortality rates. Forkhead box P2 (FOXP2) functions as an antitumor gene in various cancers. However, its role in lung cancer remains to be elucidated. The present study explored the potential role of FOXP2 in lung cancer. mRNA levels and protein expression were determined using RT-qPCR and western blotting, respectively. Functional analysis was performed using the CCK-8, Transwell and TUNEL assays. FOXP2 expression was downregulated in lung cancer. Notably, FOXP2 suppressed the proli...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Wenya Su Song Hu Lin Zhou Hui Bi Zhiying Li Source Type: research
Low ‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
In conclusion, preliminary results indicated that low-dose venetoclax combined with azacitidine is effective and safe for the treatment of older and frail patients with newly diagnosed AML, providing a new treatment option for these patients.PMID:38586209 | PMC:PMC10996028 | DOI:10.3892/ol.2024.14362 (Source: Oncology Letters)
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Chunmeng Rong Fang Yang Yalu Chen Ming Wang Cheng Ai Yuqing Luo Panpan Gao Yiqin Weng Xiaguang Huang Meier Gu Weiping Huang Yongming Xia Source Type: research
Drug resistance ‑related gene targets and molecular mechanisms in the A2780/Taxol‑resistant epithelial ovarian cancer cell line
Oncol Lett. 2024 Mar 26;27(5):232. doi: 10.3892/ol.2024.14365. eCollection 2024 May.ABSTRACTEpithelial ovarian cancer (EOC) is a fatal gynecological malignant tumor with a low 5-year survival rate. The use of the first-line chemotherapeutic drug, paclitaxel, for the treatment of EOC is associated with resistance, often leading to treatment failure. The present study investigated the gene targets in an A2780 paclitaxel-resistant EOC cell line (A2780/Taxol), and the potential underlying mechanisms using transcriptome sequencing technology and bioinformatics analysis. The transcriptome of the A2780/Taxol cell line was sequenc...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Ruihui Yang Huainian Zhang Zexin Chen Tao Zhang Peng Wei Huaguo Liang Yaoyao He Changtao Zheng Xicheng Wang Yongli Zhang Source Type: research
MicroRNA ‑373‑3p inhibits the proliferation and invasion of non‑small‑cell lung cancer cells by targeting the GAB2/PI3K/AKT pathway
Oncol Lett. 2024 Mar 22;27(5):221. doi: 10.3892/ol.2024.14353. eCollection 2024 May.ABSTRACTMicroRNAs (miRNAs) were previously demonstrated to be involved in the pathogenesis of non-small-cell lung cancer (NSCLC); however, the roles of certain miRNAs in NSCLC remain to be elucidated. The present study aimed to investigate the functions of screened miRNAs in NSCLC and the potential mechanisms. First, expression profiles of miRNAs were downloaded from the Gene Expression Omnibus (dataset no. GSE29248) and the differentially expressed miRNAs were analyzed by bioinformatics methods. Reverse transcription-quantitative PCR was u...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Xunxia Zhu Xiaoyu Chen Xuelin Zhang Liting Zhao Xiaoyong Shen Source Type: research
Efficacy and survival outcomes of alectinib vs. crizotinib in ALK ‑positive NSCLC patients with CNS metastases: A retrospective study
Oncol Lett. 2024 Mar 22;27(5):224. doi: 10.3892/ol.2024.14357. eCollection 2024 May.ABSTRACTAnaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have transformed the treatment paradigm for patients with ALK-positive non-small cell lung cancer (NSCLC). Yet the differential efficacy between alectinib and crizotinib in treating patients with NSCLC and central nervous system (CNS) metastases has been insufficiently studied. A retrospective analysis was conducted of clinical outcomes of patients with ALK-positive NSCLC and CNS metastases treated at the Shandong Cancer Centre. Based on their initial ALK-TKI treatme...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Qing Liu Ying Fu Jun Guo Chunqiu Fu Ning Tang Chufeng Zhang Xiao Han Zhehai Wang Source Type: research
Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: A case report
Oncol Lett. 2024 Mar 26;27(5):230. doi: 10.3892/ol.2024.14363. eCollection 2024 May.ABSTRACTGlioblastoma (GBM) is the most common primary malignant brain tumour in adults. The standard of care consists of surgical resection and concurrent chemoradiation, followed by adjuvant temozolomide chemotherapy. This protocol is associated with a median survival of 12-15 months, and <5% of patients survive >3 years. Ketogenic metabolic therapy (KMT) targets cancer cell metabolism by restricting glucose availability and evoking differential stress resistance and sensitization, which may augment the standard treatments and lead t...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Matthew C L Phillips Ziad Thotathil Prashanth Hari Dass Fouzia Ziad Ben G Moon Source Type: research
p160 nuclear receptor coactivator family members and their role in rare fusion ‑driven neoplasms (Review)
Oncol Lett. 2024 Mar 14;27(5):210. doi: 10.3892/ol.2024.14343. eCollection 2024 May.ABSTRACTGene fusions with translocations involving nuclear receptor coactivators (NCoAs) are relatively common among fusion-driven malignancies. NCoAs are essential mediators of environmental cues and can modulate the transcription of downstream target genes upon binding to activated nuclear receptors. Therefore, fusion proteins containing NCoAs can become strong oncogenic drivers, affecting the cell transcriptional profile. These tumors show a strong dependency on the fusion oncogene; therefore, the direct pharmacological targeting of the ...
Source: Oncology Letters - April 4, 2024 Category: Cancer & Oncology Authors: Danilo Segovia Polona Safaric Tepes Source Type: research
Clinicopathological features of cholangiolocarcinoma and impact of tumor heterogeneity on prognosis: A single institution retrospective study
In conclusion, these results suggest that it is important for CLC patients to achieve curative resection, and CLC may have a good prognosis regardless of the proportion of CLC components in a single tumor.PMID:38572060 | PMC:PMC10988194 | DOI:10.3892/ol.2024.14346 (Source: Oncology Letters)
Source: Oncology Letters - April 4, 2024 Category: Cancer & Oncology Authors: Hiroaki Sugita Shinichi Nakanuma Ryosuke Gabata Tomokazu Tokoro Ryohei Takei Mitsuyoshi Okazaki Kaichiro Kato Satoshi Takada Isamu Makino Kazuto Kozaka Kenichi Harada Shintaro Yagi Source Type: research
Effect of different preoperative nutritional treatments on postoperative recovery and clinical outcomes in patients with gastric cancer and early gastric outlet obstruction
This study aimed to evaluate the impact of different preoperative nutritional treatments on their postoperative recovery and prognosis. The present retrospective study collected data from 467 patients with gastric cancer and early gastric outlet obstruction who underwent surgery at Harbin Medical University Cancer Hospital (Harbin, China) between January 2016 and December 2018. All patients received preoperative nutritional treatment, with a mean treatment duration of 8.23±2.33 days. The present study analyzed associations and survival in different groups using χ2, independent-samples t-test, ANOVA and log-rank tests. Fu...
Source: Oncology Letters - April 4, 2024 Category: Cancer & Oncology Authors: Caixia Wang Dameng Yang Source Type: research
[Retracted] Serum miR ‑338‑5p has potential for use as a tumor marker for retinoblastoma
Oncol Lett. 2024 Mar 19;27(5):215. doi: 10.3892/ol.2024.14347. eCollection 2024 May.ABSTRACT[This retracts the article DOI: 10.3892/ol.2019.10331.].PMID:38572062 | PMC:PMC10988189 | DOI:10.3892/ol.2024.14347 (Source: Oncology Letters)
Source: Oncology Letters - April 4, 2024 Category: Cancer & Oncology Authors: Peng Zhou Xuemin Li Source Type: research
The expression of trefoil factor family member 2 in increased at an acidic pH
In conclusion, TFF2 was highly expressed under acidic conditions, implying that it may have an important function in protecting the plasma membrane from acidic environments in both normal and cancer cells. These findings warrant further investigation of TFF2 as a target of cancer therapy and diagnosis.PMID:38572063 | PMC:PMC10988190 | DOI:10.3892/ol.2024.14345 (Source: Oncology Letters)
Source: Oncology Letters - April 4, 2024 Category: Cancer & Oncology Authors: Yui Masumoto Suzuka Matsuo Natsuno Kinjou Yuka Narieda Morimasa Wada Kyoko Fujimoto Source Type: research
